Bradley L. Campbell - Dec 31, 2021 Form 4 Insider Report for AMICUS THERAPEUTICS, INC. (FOLD)

Role: Chief Operating Officer, Director
Signature: /s/ Christian Formica, Attorney-in-Fact
Stock symbol: FOLD
Transactions as of: Dec 31, 2021
Transactions value $: -$723,902
Form type: 4
Date filed: 1/4/2022, 07:58 PM
Previous filing: Dec 23, 2021
Next filing: Jan 19, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	FOLD	Common Stock	Tax liability	-$203K	-17.6K	-3.85%	$11.55	440K	Dec 31, 2021	Direct
transaction	FOLD	Common Stock	Tax liability	-$323K	-27.9K	-6.36%	$11.55	412K	Jan 2, 2022	Direct
transaction	FOLD	Common Stock	Tax liability	-$60.4K	-4.98K	-1.21%	$12.11	407K	Jan 3, 2022	Direct
transaction	FOLD	Common Stock	Options Exercise	$19.3K	+5.47K	+1.34%	$3.53	412K	Jan 3, 2022	Direct
transaction	FOLD	Common Stock	Sale	-$64.9K	-5.47K	-1.33%	$11.86	407K	Jan 3, 2022	Direct	F1, F2
transaction	FOLD	Common Stock	Award		+155K	+38.04%		561K	Jan 3, 2022	Direct	F3, F4
transaction	FOLD	Common Stock	Tax liability	-$92K	-7.37K	-1.31%	$12.48	554K	Jan 4, 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	FOLD	Stock Options (right to buy)	Options Exercise	$0	-5.47K	-8.33%	$0.00	60.2K	Jan 3, 2022	Common Stock	5.47K	$3.53	Direct	F5
transaction	FOLD	Stock Options (right to buy)	Award	$0	+284K		$0.00	284K	Jan 3, 2022	Common Stock	284K	$12.11	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2	This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.36 to $12.11. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3	Granted in the form of Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Amicus common stock.
F4	The Restricted Stock Units will vest in four equal annual installments beginning on January 3, 2023.
F5	All of the options were fully vested and exercisable as of the transaction date.
F6	These options vest and become exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter.